TEVA Pharmaceuticals USA to Standardize on MKS

Integrity Solution to Meet FDA Audit Requirements 
WATERLOO, ON, June 28 /CNW/ - MKS Inc. (TSX:MKX), a leading provider of
enterprise software configuration management (SCM) solutions for the Global
1000, today announced that TEVA Pharmaceuticals USA, the wholly-owned American
subsidiary of TEVA Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and the
leading manufacturer and distributor of generic drugs in the U.S., has
selected the MKS Integrity Solution(R) for enterprise software configuration
management (SCM). 
By securely automating IT change control and configuration management
processes, TEVA will more effectively satisfy Pharmaceutical regulations such
as the U.S. Food and Drug Administration's (FDA) 21 Code of Federal
Regulations, Part 11 (21-CFR Part 11). Additional benefits that TEVA will
realize from standardizing on the MKS Integrity Solution include: 

    -  Improved operational efficiencies from tighter integration between
       lines of business, development and IT operations. This is achieved
       through automation and enforcement of the linkage between change
       control and configuration management processes;
    -  Traceability from requirements to the software assets promoted into
       production environments will provide improved management visibility,
       control, and metrics;
    -  Enhanced cross-team communication and real-time collaboration
       improving software application quality, accuracy, reproducibility, and
    -  Enforced version control processes to improve security of software
       assets and intellectual property;
    -  Secure processes governing promotion to production will ensure no
       assets or artifacts are left behind as a change progresses through the
       lifecycle; and
    -  More efficient roll backs or identification of all assets related to a
       change implemented at any point in the past.

Tom Loane, Chief Information Officer for TEVA Pharmaceuticals USA, said,
"One of the main measures for success in the implementation of the MKS
Integrity Solution will be a reduction in the amount of paper and forms that
get manually pushed from person to person. Simply automating service request
forms and routing them via electronic workflows will result in a more
effective use of time spent managing projects." 
The MKS Integrity Solution will initially be deployed in North Wales,
Pennsylvania with future plans to deploy to other teams and locations world-wide. The future vision is to leverage MKS as the standard enterprise change
control and configuration management solution for TEVA's global operations. 
About TEVA Pharmaceuticals USA 
TEVA Pharmaceuticals USA is a wholly-owned subsidiary of Teva
Pharmaceutical Industries Ltd. Founded in 1901, Teva is Israel's largest
pharmaceutical manufacturer and a global company operating in 19 countries on
5 continents. 
About MKS 
MKS Inc. ("MKS") (TSX: MKX) provides award-winning enterprise software
configuration management (SCM) and interoperability software solutions
enabling Global 1000 companies to better manage and control the complete
process of software development. The company's family of SCM products offers
advanced technology with robust workflow, version control, and impact analysis
capabilities. Under its widely known MKS Toolkit brand, MKS also provides 
UNIX-Windows co-existence, and system administration that significantly cut
development and administrative costs and reduce time to market while enabling
enhanced performance. Founded in 1984 with over 10,000 customers worldwide,
MKS has built its brand on the foundation of advanced technology, superior
quality and extraordinary customer service. More information about MKS can be
found at, or by calling 1-800-265-2797 (US & Canada),   
+49-711-351775-0 (Germany), and +44-1483-733900 (United Kingdom). 
Copyright (C) 2004 MKS Inc. MKS, MKS Integrity Solution and MKS Toolkit
are registered trademarks of MKS Inc. All other trademarks mentioned in this
release are the property of their respective owners. 
This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially from
the statements made. When used in this document, the words "may", "would",
"could", "will", "intend", "plan", "anticipate", "believe", "estimate",
"expect" and similar expressions are intended to identify forward-looking
statements. Such statements reflect the Company's current views with respect
to future events and are subject to such risks and uncertainties. Many factors
could cause our actual results to differ materially from the statements made
including those factors detailed from time to time in filings made by the
Company with Canadian securities regulatory authorities. Should one or more of
these risks or uncertainties materialize, or should assumptions underlying the
forward looking statements prove incorrect, actual results may vary materially
from those described herein as intended, planned, anticipated or expected. The
Company does not intend and does not assume any obligation to update these
forward-looking statements. 
-0-                           06/28/2004 
/For further information: Media Contact: Alex Forbes, MKS Inc., Phone: 
(781) 359-3362, Email: aforbes(at);
To request a free copy of this organization's annual report, please go to and click on reports(at)cnw./ 
CO:  MKS Inc.
ST:  Ontario
SU:  CON  
-0- Jun/28/2004 14:00 GMT
Press spacebar to pause and continue. Press esc to stop.